Hepatitis - Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 4 PAGES: 250

More Info
									Hepatitis – Pipeline Review, H2 2011




                               Hepatitis - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1354IDB

                                                                                          Publication Date: September 2011




Hepatitis – Pipeline Review, H2 2011                                                                          GMDHC1354IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                 Page(1)
Hepatitis – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                       11
List of Figures                                                                                                      17
Introduction                                                                                                         18
     Global Markets Direct Report Coverage                                                                           18
Hepatitis Overview                                                                                                   19
Therapeutics Development                                                                                             20
     An Overview of Pipeline Products for Hepatitis                                                                  20
Hepatitis Therapeutics under Development by Companies                                                                22
Hepatitis Therapeutics under Investigation by Universities/Institutes                                                29
Late Stage Products                                                                                                  35
     Comparative Analysis                                                                                            35
Mid Clinical Stage Products                                                                                          36
     Comparative Analysis                                                                                            36
Early Clinical Stage Products                                                                                        37
     Comparative Analysis                                                                                            37
Discovery and Pre-Clinical Stage Products                                                                            38
     Comparative Analysis                                                                                            38
Hepatitis Therapeutics - Products under Development by Companies                                                     39
Hepatitis Therapeutics - Products under Investigation by Universities/Institutes                                     62
Companies Involved in Hepatitis Therapeutics Development                                                             68
     Bristol-Myers Squibb Company                                                                                    68
     Johnson & Johnson                                                                                               69
     Boehringer Ingelheim GmbH                                                                                       69
     F. Hoffmann-La Roche Ltd.                                                                                       70
     Abbott Laboratories                                                                                             71
     Vical Incorporated                                                                                              72
     United Therapeutics Corporation                                                                                 72
     Medgenics Inc.                                                                                                  73
     Valeant Pharmaceuticals International                                                                           73
     Sanofi-Aventis                                                                                                  74
     AstraZeneca PLC                                                                                                 74
     GlaxoSmithKline plc                                                                                             75
     Tekmira Pharmaceuticals Corp.                                                                                   75
     Inovio Biomedical Corporation                                                                                   76
     Idenix Pharmaceuticals, Inc.                                                                                    77
     Gilead Sciences, Inc.                                                                                           77
     Merck & Co., Inc.                                                                                               78
     Emergent BioSolutions Inc.                                                                                      79
     Lentigen Corporation                                                                                            80
     ChemDiv, Inc.                                                                                                   80
     Mochida Pharmaceutical Co., Ltd.                                                                                81
     Biotron Limited                                                                                                 81
     Novartis AG                                                                                                     82
     Samyang Corporation                                                                                             82
     Achillion Pharmaceuticals, Inc.                                                                                 83
     Cubist Pharmaceuticals, Inc.                                                                                    83


Hepatitis – Pipeline Review, H2 2011                                                      GMDHC1354IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(2)
Hepatitis – Pipeline Review, H2 2011


     Daewoong Pharmaceutical Co., Ltd.                                                                               84
     Dong-A Pharmaceutical Co., Ltd.                                                                                 84
     Hanmi Pharmaceutical Co Ltd                                                                                     85
     InterMune, Inc.                                                                                                 85
     Japan Tobacco Inc.                                                                                              86
     Meiji Holdings Co., Ltd.                                                                                        86
     Norgine Limited                                                                                                 87
     Pfizer Inc.                                                                                                     87
     Toyama Chemical Co. Ltd                                                                                         88
     Vertex Pharmaceuticals Incorporated                                                                             88
     Progenics Pharmaceuticals, Inc.                                                                                 89
     Guangzhou Pharmaceutical Company Limited                                                                        90
     Avexa Limited                                                                                                   90
     Santaris Pharma A/S                                                                                             91
     Tacere Therapeutics, Inc.                                                                                       91
     Aduro BioTech                                                                                                   91
     Astex Therapeutics Limited                                                                                      92
     CEL-SCI Corporation                                                                                             92
     Inhibitex, Inc.                                                                                                 93
     4SC AG                                                                                                          93
     Hemispherx Biopharma, Inc.                                                                                      94
     Agenix Limited                                                                                                  94
     Enzo Biochem, Inc.                                                                                              95
     Can-Fite BioPharma Ltd.                                                                                         95
     Idera Pharmaceuticals, Inc.                                                                                     96
     Intercell AG                                                                                                    96
     Ligand Pharmaceuticals Incorporated                                                                             97
     Medivir AB                                                                                                      97
     Biota Holdings Limited                                                                                          98
     NanoViricides, Inc.                                                                                             98
     Novelos Therapeutics, Inc.                                                                                      99
     Pacgen Biopharmaceuticals Corporation                                                                           99
     Patrys Limited                                                                                                 100
     Peregrine Pharmaceuticals, Inc.                                                                                100
     Pevion Biotech Ltd                                                                                             101
     Pharmasset, Inc                                                                                                101
     CytoGenix, Inc.                                                                                                102
     Amarillo Biosciences, Inc.                                                                                     102
     Anadys Pharmaceuticals, Inc                                                                                    103
     Flamel Technologies S.A.                                                                                       103
     Dynavax Technologies Corporation                                                                               104
     Transgene SA                                                                                                   104
     Immuron Limited                                                                                                105
     Lipoxen PLC                                                                                                    105
     Bukwang Pharmaceutical Co., Ltd.                                                                               106
     Miraca Holdings Inc.                                                                                           106
     Hanall Pharmaceutical Co., Ltd.                                                                                107
     MOLOGEN AG                                                                                                     108




Hepatitis – Pipeline Review, H2 2011                                                      GMDHC1354IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(3)
Hepatitis – Pipeline Review, H2 2011


     LG Life Sciences, Ltd                                                                                          108
     Samaritan Pharmaceuticals, Inc.                                                                                109
     LTT Bio-Pharma Co., Ltd.                                                                                       109
     Summit Corporation plc                                                                                         110
     Phynova Group Ltd                                                                                              110
     Innate Pharma SA                                                                                               111
     Tripep AB                                                                                                      111
     Raptor Pharmaceuticals Corp.                                                                                   112
     Digna Biotech, S.L.                                                                                            112
     Debiopharm Group                                                                                               113
     StemCells, Inc.                                                                                                113
     Maywufa Company Limited                                                                                        114
     SCYNEXIS, Inc.                                                                                                 114
     Nutri Pharma ASA                                                                                               115
     7TM Pharma A/S                                                                                                 115
     Wellstat Therapeutics Corporation                                                                              116
     Biolex Therapeutics, Inc.                                                                                      116
     Cytheris SA                                                                                                    117
     Altor BioScience Corporation                                                                                   117
     Eiger BioPharmaceuticals, Inc.                                                                                 118
     AiCuris GmbH & Co. KG                                                                                          118
     Okairos                                                                                                        119
     PTC Therapeutics, Inc.                                                                                         119
     Conatus Pharmaceuticals Inc.                                                                                   120
     Rottapharm SpA                                                                                                 120
     Presidio Pharmaceuticals, Inc.                                                                                 121
     Romark Laboratories, L.C.                                                                                      121
     Avila Therapeutics, Inc.                                                                                       122
     Intarcia Therapeutics, Inc.                                                                                    122
     REPLICor Inc.                                                                                                  123
     Biotica Technology Ltd                                                                                         123
     Sinovac Biotech Ltd.                                                                                           124
     Virobay Inc.                                                                                                   124
     Genexine Co., Ltd.                                                                                             125
     Juvaris BioTherapeutics, Inc.                                                                                  125
     NanoBio Corporation                                                                                            126
     ImmunoVaccine Technologies Inc.                                                                                126
     Oncolys BioPharma Inc.                                                                                         127
     Globeimmune, Inc.                                                                                              127
     Enanta Pharmaceuticals, Inc.                                                                                   127
     Obio Pharmaceutical Holdings Limited.                                                                          128
     Canopus BioPharma Incorporated                                                                                 128
     Kalypsys, Inc.                                                                                                 129
     PepTcell Limited                                                                                               129
     Epiphany Biosciences, Inc.                                                                                     129
     GenPhar, Inc.                                                                                                  130
     Beckpharma Limited                                                                                             130
     CureTech Ltd.                                                                                                  131




Hepatitis – Pipeline Review, H2 2011                                                      GMDHC1354IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(4)
Hepatitis – Pipeline Review, H2 2011


     TaiGen Biotechnology Co., Ltd.                                                                                 131
     Variation Biotechnologies, Inc.                                                                                131
     IRX Therapeutics, Inc.                                                                                         132
     PharmaEssentia Corporation                                                                                     132
     NasVax Ltd.                                                                                                    133
     Regulus Therapeutics Inc.                                                                                      133
     Tibotec Pharmaceuticals Ltd.                                                                                   134
     Kemin Industries, Inc.                                                                                         134
     Gaia BioPharma Limited                                                                                         135
     Vakzine Projekt Management GmbH                                                                                135
     C-Pharma, Inc.                                                                                                 135
     Galmed International Ltd.                                                                                      136
     Therapure Biopharma Inc.                                                                                       136
     Connexios Life Sciences Pvt. Ltd.                                                                              136
     iTherX Pharmaceuticals Inc.                                                                                    137
     ImQuest Life Sciences                                                                                          137
Hepatitis - Therapeutics Assessment                                                                                 138
     Assessment by Monotherapy Products                                                                             138
     Assessment by Combination Products                                                                             139
     Assessment by Route of Administration                                                                          140
     Assessment by Molecule Type                                                                                    143
Late Stage Drug Profiles                                                                                            146
     Vaniprevir - Drug Profile                                                                                      146
          Product Description                                                                                       146
          Mechanism of Action                                                                                       146
          R&D Progress                                                                                              146
     Incivek - Drug Profile                                                                                         147
          Product Description                                                                                       147
          Mechanism of Action                                                                                       147
          R&D Progress                                                                                              147
     Paclitaxel - Drug Profile                                                                                      149
          Product Description                                                                                       149
          Mechanism of Action                                                                                       149
          R&D Progress                                                                                              149
     RG442 - Drug Profile                                                                                           150
          Product Description                                                                                       150
          Mechanism of Action                                                                                       150
          R&D Progress                                                                                              150
     RG964 + Pegasys - Drug Profile                                                                                 151
          Product Description                                                                                       151
          Mechanism of Action                                                                                       151
          R&D Progress                                                                                              151
     BI 201335 - Drug Profile                                                                                       153
          Product Description                                                                                       153
          Mechanism of Action                                                                                       153
          R&D Progress                                                                                              153
     Alferon N Injection - Drug Profile                                                                             154
          Product Description                                                                                       154




Hepatitis – Pipeline Review, H2 2011                                                      GMDHC1354IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(5)
Hepatitis – Pipeline Review, H2 2011


          Mechanism of Action                                                                                       154
          R&D Progress                                                                                              154
     Heplisav - Drug Profile                                                                                        155
          Product Description                                                                                       155
          Mechanism of Action                                                                                       155
          R&D Progress                                                                                              155
     NOV-205 - Drug Profile                                                                                         157
          Product Description                                                                                       157
          Mechanism of Action                                                                                       157
          R&D Progress                                                                                              157
     Alinia - Drug Profile                                                                                          158
          Product Description                                                                                       158
          Mechanism of Action                                                                                       158
          R&D Progress                                                                                              158
     TMC435 - Drug Profile                                                                                          160
          Product Description                                                                                       160
          Mechanism of Action                                                                                       160
          R&D Progress                                                                                              160
     Consensus Interferon + Ribavirin - Drug Profile                                                                161
          Product Description                                                                                       161
          Mechanism of Action                                                                                       161
          R&D Progress                                                                                              161
     Pioglitazone - Drug Profile                                                                                    162
          Product Description                                                                                       162
          Mechanism of Action                                                                                       162
          R&D Progress                                                                                              162
     Infliximab + Pegintron + Ribavirin - Drug Profile                                                              163
          Product Description                                                                                       163
          Mechanism of Action                                                                                       163
          R&D Progress                                                                                              163
     Ciclosporin - Drug Profile                                                                                     164
          Product Description                                                                                       164
          Mechanism of Action                                                                                       164
          R&D Progress                                                                                              164
     Erythropoietin Beta - Drug Profile                                                                             165
          Product Description                                                                                       165
          Mechanism of Action                                                                                       165
          R&D Progress                                                                                              165
     Pegaferon + Ribavirin - Drug Profile                                                                           166
          Product Description                                                                                       166
          Mechanism of Action                                                                                       166
          R&D Progress                                                                                              166
     Hecolin - Drug Profile                                                                                         167
          Product Description                                                                                       167
          Mechanism of Action                                                                                       167
          R&D Progress                                                                                              167
     AdoMet + Betaine + Pegylated Interferon Alpha 2b + Ribavirin - Drug Profile                                    168
          Product Description                                                                                       168




Hepatitis – Pipeline Review, H2 2011                                                      GMDHC1354IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(6)
Hepatitis – Pipeline Review, H2 2011


          Mechanism of Action                                                                                       168
          R&D Progress                                                                                              168
     TMC435 + Ribavirin + PEGIFNalpha-2A - Drug Profile                                                             169
          Product Description                                                                                       169
          Mechanism of Action                                                                                       169
          R&D Progress                                                                                              170
     Hepatitis A Vaccine - Drug Profile                                                                             171
          Product Description                                                                                       171
          Mechanism of Action                                                                                       171
          R&D Progress                                                                                              171
     Boceprevir + Peginterferon Alfa-2b + Ribavirin - Drug Profile                                                  172
          Product Description                                                                                       172
          Mechanism of Action                                                                                       172
          R&D Progress                                                                                              172
     Boceprevir + Peginterferon Alfa-2b + Ribavirin + Erythropoietin - Drug Profile                                 174
          Product Description                                                                                       174
          Mechanism of Action                                                                                       174
          R&D Progress                                                                                              174
     Pegylated Interferon Alfa-2a + Ribavirin - Drug Profile                                                        175
          Product Description                                                                                       175
          Mechanism of Action                                                                                       175
          R&D Progress                                                                                              175
     Lamivudin + Colchicine - Drug Profile                                                                          176
          Product Description                                                                                       176
          Mechanism of Action                                                                                       176
          R&D Progress                                                                                              176
     Pegylated Interferon Alfa-2a + Adefovir - Drug Profile                                                         177
          Product Description                                                                                       177
          Mechanism of Action                                                                                       177
          R&D Progress                                                                                              177
     Entecavir + Branched-Chain Amino Acids - Drug Profile                                                          178
          Product Description                                                                                       178
          Mechanism of Action                                                                                       178
          R&D Progress                                                                                              178
     Peginterferon Alfa-2a + Ribavirin - Drug Profile                                                               179
          Product Description                                                                                       179
          Mechanism of Action                                                                                       179
          R&D Progress                                                                                              179
     Peginterferon Alpha-2a + Ribavirin + Meloxicam - Drug Profile                                                  180
          Product Description                                                                                       180
          Mechanism of Action                                                                                       180
          R&D Progress                                                                                              180
     MK7009 + Pegintron + Rebetol - Drug Profile                                                                    181
          Product Description                                                                                       181
          Mechanism of Action                                                                                       181
          R&D Progress                                                                                              182
     Pioglitazone - Drug Profile                                                                                    183
          Product Description                                                                                       183




Hepatitis – Pipeline Review, H2 2011                                                      GMDHC1354IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(7)
Hepatitis – Pipeline Review, H2 2011


          Mechanism of Action                                                                                                  183
          R&D Progress                                                                                                         183
     Irbesartan - Drug Profile                                                                                                 184
          Product Description                                                                                                  184
          Mechanism of Action                                                                                                  184
          R&D Progress                                                                                                         184
     Peginterferon A-2a + Ribavirin - Drug Profile                                                                             185
          Product Description                                                                                                  185
          Mechanism of Action                                                                                                  185
          R&D Progress                                                                                                         185
     DTaP-IPV-HB-PRP~T + Prevnar - Drug Profile                                                                                186
          Product Description                                                                                                  186
          Mechanism of Action                                                                                                  186
          R&D Progress                                                                                                         186
     Prednisolone + N Acetyl Cysteine - Drug Profile                                                                           188
          Product Description                                                                                                  188
          Mechanism of Action                                                                                                  188
          R&D Progress                                                                                                         188
     Interferon Alpha-2b + Ribavirin + Interferon-Gamma - Drug Profile                                                         189
          Product Description                                                                                                  189
          Mechanism of Action                                                                                                  189
          R&D Progress                                                                                                         189
     Lopinavir + Ritonavir + Nucleoside Reverse Transcriptase Inhibitors + PEG-IFNa 2a + Ribavirin - Drug Profile              191
          Product Description                                                                                                  191
          Mechanism of Action                                                                                                  191
          R&D Progress                                                                                                         192
     Losartan - Drug Profile                                                                                                   193
          Product Description                                                                                                  193
          Mechanism of Action                                                                                                  193
          R&D Progress                                                                                                         193
     Entecavir - Drug Profile                                                                                                  194
          Product Description                                                                                                  194
          Mechanism of Action                                                                                                  194
          R&D Progress                                                                                                         194
     Pegaferon + Ribavirin - Drug Profile                                                                                      195
          Product Description                                                                                                  195
          Mechanism of Action                                                                                                  195
          R&D Progress                                                                                                         195
     Pegintron + Ribavirin - Drug Profile                                                                                      196
          Product Description                                                                                                  196
          Mechanism of Action                                                                                                  196
          R&D Progress                                                                                                         196
     Nitazoxanide - Drug Profile                                                                                               197
          Product Description                                                                                                  197
          Mechanism of Action                                                                                                  197
          R&D Progress                                                                                                         197
     Pioglitazone + Pegylated Interferon + Ribavirin - Drug Profile                                                            199
          Product Description                                                                                                  199




Hepatitis – Pipeline Review, H2 2011                                                                 GMDHC1354IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                         Page(8)
Hepatitis – Pipeline Review, H2 2011


          Mechanism of Action                                                                                       199
          R&D Progress                                                                                              199
     IMD2 - Drug Profile                                                                                            201
          Product Description                                                                                       201
          Mechanism of Action                                                                                       201
          R&D Progress                                                                                              201
     Hexaxim - Drug Profile                                                                                         202
          Product Description                                                                                       202
          Mechanism of Action                                                                                       202
          R&D Progress                                                                                              202
     DEB025 + Peg-IFN Alfa-2a + Ribavirin - Drug Profile                                                            203
          Product Description                                                                                       203
          Mechanism of Action                                                                                       203
          R&D Progress                                                                                              203
     DTaP-HepB - Drug Profile                                                                                       204
          Product Description                                                                                       204
          Mechanism of Action                                                                                       204
          R&D Progress                                                                                              204
     DtwP-HB-Hib (Recon) Vaccine - Drug Profile                                                                     205
          Product Description                                                                                       205
          Mechanism of Action                                                                                       205
          R&D Progress                                                                                              205
     DtwP-HB Vaccine - Drug Profile                                                                                 206
          Product Description                                                                                       206
          Mechanism of Action                                                                                       206
          R&D Progress                                                                                              206
     Silymarin - Drug Profile                                                                                       207
          Product Description                                                                                       207
          Mechanism of Action                                                                                       207
          R&D Progress                                                                                              207
     BI 201335 + Pegylated Interferon Alpha + Ribavirin - Drug Profile                                              208
          Product Description                                                                                       208
          Mechanism of Action                                                                                       208
          R&D Progress                                                                                              208
     Peginterferon Alfa-2b + Ribavirin + Vitamin D - Drug Profile                                                   209
          Product Description                                                                                       209
          Mechanism of Action                                                                                       209
          R&D Progress                                                                                              209
     V419 + Pentacel + Prevnar 13 + RotaTeq - Drug Profile                                                          210
          Product Description                                                                                       210
          Mechanism of Action                                                                                       210
          R&D Progress                                                                                              210
     BMS-790052 + Pegylated Interferon Alfa 2a + Ribavirin - Drug Profile                                           212
          Product Description                                                                                       212
          Mechanism of Action                                                                                       212
          R&D Progress                                                                                              212
     Lamivudine + Adefovir - Drug Profile                                                                           214
          Product Description                                                                                       214




Hepatitis – Pipeline Review, H2 2011                                                      GMDHC1354IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(9)
Hepatitis – Pipeline Review, H2 2011


          Mechanism of Action                                                                                                       214
          R&D Progress                                                                                                              214
     Telbivudine + Adefovir - Drug Profile                                                                                          215
          Product Description                                                                                                       215
          Mechanism of Action                                                                                                       215
          R&D Progress                                                                                                              215
     Nitazoxanide + Pegylated Interferon Alfa 2a + Ribavirin - Drug Profile                                                         216
          Product Description                                                                                                       216
          Mechanism of Action                                                                                                       216
          R&D Progress                                                                                                              216
     Silymarin - Drug Profile                                                                                                       217
          Product Description                                                                                                       217
          Mechanism of Action                                                                                                       217
          R&D Progress                                                                                                              217
     DTP-HepB-Polio-Hib - Drug Profile                                                                                              218
          Product Description                                                                                                       218
          Mechanism of Action                                                                                                       218
          R&D Progress                                                                                                              218
     Ribavirin + Peginterferon Alpha-2a - Drug Profile                                                                              219
          Product Description                                                                                                       219
          Mechanism of Action                                                                                                       219
          R&D Progress                                                                                                              219
     Pentoxiphylline + Vitamin E - Drug Profile                                                                                     220
          Product Description                                                                                                       220
          Mechanism of Action                                                                                                       220
          R&D Progress                                                                                                              220
     V419 + Daptacel + PedvaxHIB + Prevnar 13 + RotaTeq - Drug Profile                                                              221
          Product Description                                                                                                       221
          Mechanism of Action                                                                                                       221
          R&D Progress                                                                                                              222
     VX-950 + Pegasys + Copegus - Drug Profile                                                                                      223
          Product Description                                                                                                       223
          Mechanism of Action                                                                                                       223
          R&D Progress                                                                                                              223
     Entecavir + Pegasys - Drug Profile                                                                                             225
          Product Description                                                                                                       225
          Mechanism of Action                                                                                                       225
          R&D Progress                                                                                                              225
Hepatitis Therapeutics – Drug Profile Updates                                                                                       226
Hepatitis Therapeutics - Discontinued Products                                                                                      236
     Hepatitis - Featured News                                                                                                      238
          Sep 20, 2011: INCIVO Receives European Approval For Treatment Of Genotype-1 Chronic Hepatitis C                           238
          Sep 19, 2011: Inhibitex Commences Dosing Of Phase II Clinical Trial Of INX-189 In HCV Patients                            239
          Sep 19, 2011: Shark Compound Proves Potential As Drug To Treat Human Viruses, Says Georgetown University Medical Center
          Researcher                                                                                                                239
          Sep 19, 2011: Shark Compound Proves Potential As Drug To Treat Human Viruses, Says Georgetown University Medical Center
          Researcher                                                                                                                241
          Sep 19, 2011: Shark Compound Proves Potential As Drug To Treat Human Viruses, Says Georgetown University Medical Center
          Researcher                                                                                                                242




Hepatitis – Pipeline Review, H2 2011                                                                GMDHC1354IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                             Page(10)
Hepatitis – Pipeline Review, H2 2011


          Sep 18, 2011: Dynavax Reports Complete Results From HEPLISAV Phase III Trial In Healthy Adults Over Age 40                         243
          Sep 17, 2011: Bristol-Myers Squibb Announces Results From Phase II Clinical Trial Of BMS-790052                                    244
          Sep 16, 2011: Dynavax To Report Additional Immunogenicity Data For HEPLISAV Phase III Trial                                        246
          Sep 15, 2011: Tibotec Announces Publication Of Positive Data On Phase III Clinical Trial Of Incivo In Untreated Genotype-1 Chronic HCV
          Patients                                                                                                                            246
          Sep 13, 2011: Pharmasset Initiates Phase IIb Interferon-Free Trial Of PSI-7977 And PSI-938 For All HCV Genotypes                   247
Appendix                                                                                                                                     249
     Methodology                                                                                                                             249
          Coverage                                                                                                                           249
          Secondary Research                                                                                                                 249
          Primary Research                                                                                                                   249
          Expert Panel Validation                                                                                                            250
     Contact Us                                                                                                                              250
     Disclaimer                                                                                                                              250




Lis t o f Ta b le s
Number of Products Under Development for Hepatitis, H2 2011                                                                                   20

Products under Development for Hepatitis – Comparative Analysis, H2 2011                                                                      21

Number of Products under Development by Companies, H2 2011                                                                                    23

Number of Products under Development by Companies, H2 2011                                                                                    24

Number of Products under Development by Companies, H2 2011                                                                                    25

Number of Products under Development by Companies, H2 2011                                                                                    26

Number of Products under Development by Companies, H2 2011                                                                                    27

Number of Products under Development by Companies, H2 2011                                                                                    28

Number of Products under Investigation by Universities/Institutes, H2 2011                                                                    30

Number of Products under Investigation by Universities/Institutes, H2 2011                                                                    31

Number of Products under Investigation by Universities/Institutes, H2 2011                                                                    32

Number of Products under Investigation by Universities/Institutes, H2 2011                                                                    33

Number of Products under Investigation by Universities/Institutes, H2 2011                                                                    34

Comparative Analysis by Late Stage Development, H2 2011                                                                                       35

Comparative Analysis by Mid Clinical Stage Development, H2 2011                                                                               36

Comparative Analysis by Early Clinical Stage Development, H2 2011                                                                             37

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011                                                                 38

Products under Development by Companies, H2 2011                                                                                              39

Products under Development by Companies, H2 2011                                                                                              40

Products under Development by Companies, H2 2011                                                                                              41

Products under Development by Companies, H2 2011                                                                                              42

Products under Development by Companies, H2 2011                                                                                              43




Hepatitis – Pipeline Review, H2 2011                                                                 GMDHC1354IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                     Page(11)
Hepatitis – Pipeline Review, H2 2011


Products under Development by Companies, H2 2011                                                                     44

Products under Development by Companies, H2 2011                                                                     45

Products under Development by Companies, H2 2011                                                                     46

Products under Development by Companies, H2 2011                                                                     47

Products under Development by Companies, H2 2011                                                                     48

Products under Development by Companies, H2 2011                                                                     49

Products under Development by Companies, H2 2011                                                                     50

Products under Development by Companies, H2 2011
								
To top